SMC Decisions — 7 September 2026

The Scottish Medicines Consortium published advice on eight medicines on 7 September 2026. All eight were accepted:1 Eight high-cost specialist medicines accepted in a single month is an unusually high volume for the SMC. Blueteq comment: All eight medicines accepted in September would typically require prior-approval forms in a digital HCD governance system. Atidarsagene autotemcel […]

NICE Technology Appraisals

NICE published final draft guidance on 3 September 2026 recommending mirdametinib (Ezmekly®) for the treatment of neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas in children and young people aged 2–17 years who require systemic therapy.1 Mirdametinib is a MEK inhibitor indicated where tumours are not amenable to surgery. The eligible population in England is approximately 200 […]